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Abstract
Background: Device-associated infections due to biofilm-producing methicillin-resistant Staphylococcus aureus
(MRSA) have been recently associated with the failure of antibiotic treatment and decolonization measures. The
goal of our study was to evaluate the extent to which the formation of biofilms influenced the efficacy of topical
decolonization agents or disinfectants such as mupirocin (MUP), octenidine (OCT), chlorhexidine (CHG),
polyhexanide (POL), and chloroxylenol (CLO).
Methods: Bacterial killing in biofilms by the disinfectants and MUP was determined as the reduction [%] in
metabolic activity determined by a biofilm viability assay that uses kinetic analysis of metabolic activity.
The test substances were diluted in water with standardized hardness (WSH) at 25 °C at the standard
concentration as well as half the standard concentration to demonstrate the dilution effects in a practical
setting. The tested concentrations were: CHG 1%, 2%; OCT 0.1%, 0.05%; PH 0.04%, 0.02%; and CLO 0.12%, 0.
24%. A test organism suspension, 1 mL containing ~1 × 109 bacterial cells/mL, and 1 mL of sterile WSH
were mixed and incubated for six different exposure times (15 s, 1, 3, 5, 10 and 20 min) after the test
substance was added.
Additionally, the bactericidal effects of all substances were tested on planktonic bacteria and measured as the
log10 reduction.
Results: The disinfectants OCT and CHG showed good efficacy in inhibiting MRSA in biofilms with
reduction rates of 94 ± 1% and 91 ± 1%, respectively. POL, on the other hand, had a maximum efficacy of
only 81 ± 7%. Compared to the tested disinfectants, MUP showed a significantly lower efficacy with <20%
inhibition (p < .05). Bactericidal effects were the greatest for CHG (log10 reduction of 9.0), followed by
OCT (7.7), POL (5.1), and CLO (6.8). MUP, however, showed a very low bactericidal effect of only 2.1. Even
when the exposure time was increased to 24 h, 2% MUP did not show sufficient bactericidal effect.
Conclusions: Our data provide evidence that OCT and CHG are effective components for disinfection of
MRSA-biofilms. On the other hand, exposure to MUP at the standard concentrations in topical
preparations did not effectively inhibit MRSA-biofilms and also did not show adequate bactericidal effects.
Combining an MUP-based decolonization regimen with a disinfectant such as OCT or CHG could decrease
decolonization failure.
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Background
Methicillin-resistant and biofilm-forming Staphylococcus
aureus (MRSA) isolates have become a common clinical
problem [1]. In recent years, MRSA incidences seemed
to be decreasing, and the focus of infection control spe-
cialists was multidrug-resistant Gram-negative bacteria
[2–4]. However, Public Health England recently reported
an alarming 26% increase in MRSA bloodstream infec-
tions [5]. Although the rise in numbers coincided with
the Department of Health’s change in policy on screen-
ing for MRSA, from universal to targeted screening, it
underlines the fact that MRSA cannot be considered
“out of the picture”. The formation of biofilms as a reac-
tion to therapeutic interventions, which can lead to
increased antimicrobial resistance and a higher chance
of treatment failure, is being increasingly recognized as
an infection control problem [6, 7]. Accordingly, treat-
ment and decolonization failure occur more frequently
when topical drugs like mupirocin are used against
biofilm-forming microorganisms [8–12].
The organization of bacteria into biofilms is the com-
mon mode of bacterial survival, since this form increases
their ability to withstand antibiotics, disinfectants, and
host responses. Biofilm formation is a multifarious, con-
trolled bacterial process that induces many additional
functional and phenotypic alterations, including loss of
motility, reduced growth rate, increased surface adhe-
sion, as well as an altered susceptibility to the host
response [13–17]. An association with biofilm formation
has been reported for many hospital-acquired infections,
such as urinary tract and catheter-related bloodstream
infections as well as infections of implanted medical
devices including indwelling catheters, artificial heart
valves, orthopedic prostheses, or osteosynthesis mate-
rials [7, 18–24]. Colonization with MRSA is associated
with a high risk of acquiring an MRSA infection during
hospital stays [25, 26]. Decolonization may reduce the
risk of MRSA infection in individual carriers and prevent
transmission to other patients [25]. However, the most
commonly used agent for decolonization, mupirocin,
comes with a considerable risk of resistance if widely
employed [26]. There have been many other attempts to
eradicate carriage, mostly with topical agents, but suc-
cess rates have not been consistent or applicable to all
populations [26], and even mupirocin decolonization
success rates can be low [25]. Many international guide-
lines (i.e., in Germany, Ireland, Netherlands, Slovenia)
already state that attempts at decolonization are unlikely
to be successful in patients with chronic skin conditions,
ulcers, or in-dwelling catheters [27–30]. Some studies,
however, showed that decolonization can be effective in
patients with lines and catheters [25] and that the ina-
bility to decolonize was most closely associated with fail-
ure to use a standardized decolonization protocol [31].
However, to our knowledge, no study has been able to
identify a consistent subgroup of patients at higher risk
for decolonization failure. Perhaps, the focus has been
on the wrong variable in the equation, and the reason
for decolonization failure is not the patient but the
bacterium and its biofilm-forming capacities. Alarm-
ingly, one study on biofilm formation among MRSA
nasal carriers showed that all of the isolated MRSA had
the ability to form biofilms [7]. The goal of our study,
therefore, was to evaluate the extent to which MRSA
biofilms are influenced by the use of the topical
decolonization antibiotic MUP and the widely used top-
ical disinfectants, i.e., octenidine (OCT), chlorhexidine
(CHG), polyhexanide (POL), and chloroxylenol (CLO).
Methods
Bacterial isolates
To ensure practical relevance, clinical MRSA isolates, as
well as American Type Culture Collection (Manassas,
VA, USA; ATCC®) control strains, were tested in this
study. Clinical isolates were recovered as follows: screen-
ing swab samples were inoculated on Columbia 5%
sheep blood agar plate (BD Diagnostics, Sparks, USA)
and chromogenic plates for MRSA detection (ChromAgar
MRSA II, BD) and incubated under aerobic conditions for
48 h at 36 °C. If growth on chromogenic plates was
detected, identification by matrix-assisted laser desorption
ionization-time-of-flight mass spectrometry (MALDI-
TOF MS) (Bruker Daltonics, Bremen, Germany) was
performed [32]. Agglutination with Pastorex® StaphPlus
(Alere, Jena, Germany) was performed to confirm S.
aureus growth. Susceptibility testing was performed by
VITEK2 (bioMérieux) and results were interpreted ac-
cording to EUCAST breakpoints. Biofilm-forming capaci-
ties of each isolate were determined by the crystal violet
staining technique (data not shown). Six representative
isolates with significant biofilm-forming capacity com-
pared to the standard disinfectant efficacy test isolate
ATCC® 6538™, according to ATCC® product sheet, were
selected and used for further testing.
Preparation of antimicrobials and neutralizer
For standardization of experimental conditions, in each
experiment, water of standardized hardness (WSH) was
prepared with a total hardness of 300 ppm (CaCO3) with
0.119 g/l magnesium chloride (Carl Roth, Karlsruhe,
Germany), 0.277 g/l calcium chloride (Carl Roth), and
0.28 g/l sodium hydrogen carbonate (Carl Roth). WSH at
a pH of 7.0 ± 0.2 at 25 °C was used as a diluent. Tryptic
soy broth (TSB) containing lecithin, Tween 80, histidine,
and sodium thiosulfate neutralizing agent (all from Merck
Millipore, Darmstadt, Germany) (LTHTh) was used in
both treatment and control groups, immediately following
disinfection according to the manufacturer’s instructions.
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The media and neutralizers used in this study were
approved for effective neutralization of the applied disin-
fectants prior to the experiments (data not shown).
Biofilm viability assay
The MRSA isolates were cultured on Columbia blood
agar plates at 37 °C for 12 h. Bacterial killing in biofilms
was determined as reduction [%] in metabolic activity
using a kinetic biofilm viability assay as previously de-
scribed [33]. Briefly, the test substances were diluted in
WSH at 25 °C at the standard concentration as well as
half the standard concentration to demonstrate the dilu-
tion effects in a practical setting. For testing of anti-
microbial effects on the bacterial metabolic activity in
biofilms, the antimicrobial substances were diluted in
WSH at standard working concentrations 0.05% and
0.1% (w/v) for OCT (TCI, Eschborn, Germany), 1% and
2% (w/v) for CHG (Sigma Aldrich, Taufkirchen,
Germany), 0.02% and 0.04% (w/v) for POL (Fagron,
Barsbuettel, Germany), 0.12% and 0.24% (w/v) for CLO
(Sigma Aldrich), and 1% and 2% (w/v) for MUP
(Fagron). Each preparation was applied to the prepared
biofilms for different exposure times of 15 s, 1, 3, 5, 10
and 20 min at 37°Cfor the OCT, CHG, POL, and CLO
solutions. Prolonged exposure times of up to 3.5 h were
used for MUP to analyze the different mode of action of
this substance. To take into account the different mode
of action of MUP compared to disinfectants, extended
exposure times of up to 3.5 h were used for this substance
adapted to simplified testing protocols for determination of
bactericidal activity on Staphylococcus aureus isolates as
previously described [34]. After exposure, the remaining
metabolic activity in the biofilm was measured. Biofilms
exposed to WSH alone (without supplements) served as a
control for 100% viability or 0% inhibition. The bacterial
killing by the disinfectants in the biofilms was determined
as the reduction [%] in metabolic activity as compared to
the untreated controls.
Live/dead staining of biofilms
To analyze the killing effects on the bacterial cells in bio-
films, biofilms were cultured on glass coverslips (Carl
Roth). After incubation, biofilms were washed twice in a
0.9% NaCl solution. Then, 100 μL M63 minimal medium
consisting of 0.015 M ammonium hydrogen sulfate
(Carl Roth), 0.1 M potassium dihydrogen sulfate
(Sigma-Aldrich, Steinheim, Germany), 1.8 μM iron
sulfate heptahydrate (Carl Roth), 1 mM magnesium
sulfate heptahydrate, 2 ml/L glycerol (VWR Chemi-
cals, Darmstadt, Germany) and 1 g/L casein hydrolys-
ate standard (Carl Roth)containing disinfectants in
different concentrations was added, and the biofilms
were incubated for up to 2 h at 37 °C. After incubation,
biofilms were washed twice in 0.9% NaCl solution and
stained using the LIVE/DEAD BacLight Bacterial Viability
Kit (Molecular Probes, Leiden, Netherlands) according to
the manufacturer’s instructions. Stained biofilms were
analyzed after mounting on object slides by using a BZ
8100 fluorescence microscope (Keyence, Neu-Isenburg,
Germany) in the green fluorescent band for Syto 9 stain-
ing of dead and living bacterial cells, and in red fluores-
cent band for selective propidium iodide staining of dead
cells or cells with disturbed cell integrity; therefore, yellow
color in the overlay image is indicative of dead bacteria in
the biofilm.
Determination of bactericidal activity
For determination of bactericidal effects, the antimi-
crobial substances were diluted in WSH at standard
Fig. 1 Disinfectant efficacy on MRSA-biofilms Reduction of metabolic
activity (%) in bacterial biofilms ± standard deviation (SD) after
disinfectant treatment at different concentrations and for varying
exposure times, determined by a kinetic metabolic assay
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working concentrations 0.1% (w/v) for OCT, 2% for
CHG, 0.04% (w/v) for POL, 0.24% (w/v) for CLO,
and 2% (w/v) for MUP, and at least 1x109 bacterial
cells were added for different exposure times. Each
sample was tested for the surviving bacterial count
by membrane filtration of the disinfectant solution
through a 0.45-μm nitrocellulose membrane (Sartor-
ius Stedim, Göttingen, Germany) followed by rinsing
three times using 100 ml of a NaCl-peptone solution
(Becton Dickinson, Heidelberg, Germany) for removal
of remaining disinfectant. Afterwards, the filters were
transferred to Caso Agar containing LTHTh as a
neutralizer (Merck Millipore, Darmstadt, Germany).
The neutralization and washing steps were validated
for effective neutralization of the tested disinfectants
prior to this study (data not shown). The media
were incubated for 48 h at 37 °C and then checked
for microbial growth. Colony forming units (CFUs)
were counted and the Log10 reduction factor (LRF10)
was calculated compared to the untreated controls as
a measure of the bactericidal effect.
Statistics
For descriptive purposes, arithmetic mean value, stand-
ard deviation, median, interquartile range, and cumula-
tive frequencies were calculated as appropriate. P values
of ≤ .05 were considered statistically significant. Statis-
tical analysis was performed using the SPSS ver. 21.0
statistical package (SPSS, Chicago, IL).
Results
The effects of the different disinfectants on metabolic
activity in established MRSA biofilms were tested using
a kinetic metabolic assay (Fig. 1) [33]. OCT showed
moderate efficacy in inhibiting microbial metabolic ac-
tivity with 94 ± 1% inhibition after only 15 s of exposure
and at a concentration of 0.05%. The overall efficacy of
OCT on MRSA biofilm inhibition was not significantly
changed due to modifications of the concentration used,
ranging from 0.05% to 1%, or due to modifications of
the exposure time, ranging from 15 s to 20 min. The CHG
solution showed a efficacy of 91 ± 1% in inhibiting micro-
bial metabolic activity after 3 min of exposure to a 1%
CHG solution. Furthermore, after 1 min of exposure, there
was no significant increase in efficacy of CHG on MRSA
biofilms for the tested concentration range. POL, in con-
trast, yielded a lower overall medium efficacy of inhibition
of metabolic activity in biofilms of 65.4 ± 11%, while the
efficacy was strongly dependent on the applied exposure
time. CLO showed the lowest efficacy of 15.8 ± 27%. Add-
itionally, the efficacy of CLO was strongly dependent on
the applied exposure time and concentration.
On the other hand, the antibiotic MUP showed detect-
able efficacy in inhibiting metabolic activity in MRSA
biofilms after short exposure times (Fig. 2). To rule out
that the lack of efficacy is caused by the different mode
of action of MUP, namely the inhibition of bacterial pro-
tein synthesis, the exposure times for MUP on the
MRSA biofilms were extended to up to 3.5 h. Even after
Fig. 2 MUP efficacy on MRSA-biofilms and planktonic bacteria Upper panel: Reduction of metabolic activity (%) in bacterial biofilms ± SD after
MUP treatment at different concentrations and varying exposure times, determined by a kinetic metabolic assay. Lower panel: Bactericidal activity
of a 2% MUP solution on planktonic MRSA, shown as reduction of cell counts [CFU] compared to untreated controls in WSH
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3.5 h of exposure to 2% MUP solution, the level of meta-
bolic inhibition of the bacteria in the MRSA biofilms
did not exceed 20%, while significant inhibition (p <
0.05) was reached after at least 2 h of. Taken to-
gether, 2% MUP showed between 1 and 20% inhib-
ition of the metabolic activity of MRSA biofilms after
exposure times of up to 3.5 h (Fig. 2).
Exposure of biofilms to OCT and CHG solutions led
to extensive damage of bacterial cell integrity as indi-
cated by positive propidium iodide staining (Fig. 3),
whereas the viability of bacteria in biofilms and the cell
integrity of the same strain and maturation state were
only weakly affected by POL and CLO and only slightly
affected by exposure to 2% MUP for 2 h, similar to that
seen in the exposure to WSH only. Additionally, no
restrictions of biofilm permeation could be detected for
the OCT- and CHG-mediated biofilm killing effects as
indicated by the fact that the damage to the biofilm was
not restricted to the outside layer.
Regarding the bactericidal effects, each of the four
tested disinfectants, OCT, CHG, POL, and CLO, reached
a LRF10 using planktonic MRSA of at least 4 after 1 h of
exposure. In contrast, exposure of MRSA to a 2% MUP
solution yielded an LRF10 of 0.11 ± 0.2 after 1 h and
2.3 ± 1.8 after 24 h of exposure (Fig. 2).
Discussion
Our data provide evidence that OCT and CHG are
effective components for disinfection of MRSA biofilms
in vitro and that exposure to MUP at the standard
concentrations in topical preparations up to 2% does not
effectively inhibit the metabolic activity of MRSA bio-
films, even after the prolonged exposure of 3.5 h. The
limited efficacy of MUP against the bacteria in biofilms
has previously been described [35]. The biofilm probably
provides a physical barrier for MUP so that only insuffi-
cient concentrations are reached in the bacteria them-
selves. Therefore, biofilm formation could influence
development of resistance since bacteria in biofilms sim-
ply might have more time to adapt to low concentrations
of MUP. However, further studies are needed to evaluate
actual interactions of MUP with bacterial biofilms.
Nevertheless, our results show that MUP did not have
significant bactericidal effects even on planktonic bacteria.
In conclusion, MUP has mainly bacteriostatic effects, i.e.,
inhibition of bacterial growth and reproduction, and only
Fig. 3 Killing and permeation of MRSA-biofilms by antimicrobials Live/dead-staining using Syto 9 and propidium iodide stains of MRSA biofilms
after exposure to WSH, 0.1% OCT, 2% CHG, 0.24% POL, 0.24% CLO, and 2% MUP for varying exposure times. Green: bacteria in biofilm; red:
bacterial cell death or defective bacterial cell integrity; yellow: dead bacteria in biofilm
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minor effects when bacteria are in biofilms. Biofilms might
be the missing link in understanding the rapid develop-
ment of resistance when MUP-based regimens are used
routinely among general inpatient populations.
One limitation of our study is that we cannot estimate
the fraction of MRSA strains that are strong biofilm for-
mers. However, this issue should be addressed in future
studies. As previously mentioned, one study on 810 nasal
carriers of S. aureus and MRSA showed that all isolated
MRSA strains were biofilm formers; however, only 34.6%
were medium to strong biofilm producers [7]. The larger
the fraction of strong biofilm formers among MRSA
strains, the more impact a change in the decolonization
regimen will have.
Conclusions
The standard MRSA decolonization protocols at referral at
our health care facility consist of 5 days of MUP treatment
as nasal ointment and additional antiseptic washing of body
and daily change of bed linen. Our data suggest that com-
bining an MUP-based decolonization regimen with a disin-
fectant such as OCT or CHG could increase the efficacy of
decolonization in patients colonized with biofilm-forming
MRSA. In patients who failed the first decolonization at-
tempt, one possible approach could be to change the 5 days
of MUP treatment of the standard decolonization regimen
to (1) two days of primary disinfection with either OCT or
CHG as a nasal ointment followed by (2) three days of
treatment with MUP for suppression of re-colonization.
Obviously, this new regimen needs to be evaluated as
randomized-controlled trial. Decolonization studies using
OCT already show good decolonization rates (67%); how-
ever, to our knowledge, no long-lasting effects with regards
to re-colonization have yet been reported [36].
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